13F Holdings
中文EN

BETRF BetterLife Pharma Inc. IFRS

Pharmaceutical Preparations · OTC · SEC CIK 1464165 · Reporting currency CAD · Fiscal year ends 01/31

Financial factors as of 2025-01-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-21.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,280.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3,372.6%
Debt / equity—
Current ratio—
Interest coverage-30.29x

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-545.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY2025*2025-01-31FY2024*2024-01-31FY2023*2023-01-31FY2022*2022-01-31FY2021*2021-01-31
Income statement
Revenue—————
R&D expense424,337570,9472.68M5.42M284,700
SG&A expense260,500271,731280,467425,8651.74M
Operating income-5.00M-3.24M-9.46M——
Interest expense165,08745,54411,49151,7617,046
Pretax income—-2.90M-9.37M-11.99M-36.35M
Net income-3.52M-2.89M-9.02M-12.16M-36.35M
EBITDA-5.00M-3.24M-9.44M——
EPS (basic)————-1.34
EPS (diluted)-0.03-0.03-0.10-0.16-1.34
Weighted avg. shares (diluted)———438,0950
Balance sheet
Cash & equivalents8,18037,3848,307173,513154,722
Receivables11,64439,53617,196324,993520,122
Current assets——74,7271.14M1.33M
Intangibles————0
Total assets224,963324,74674,7271.16M1.34M
Current liabilities7.54M7.35M7.15M4.14M5.85M
Short-term debt—50,05280,00040,0000
Long-term debt—49,115034,5590
Total debt—99,16780,00074,5590
Total liabilities7.59M8.02M7.61M5.04M5.98M
Shareholders' equity-10.68M-10.81M-10.73M-3.88M-4.61M
Net debt—61,78371,693-98,954-154,722
Shares outstanding43.49M52.81M30.14M31.26M—
Cash flow statement
Operating cash flow-2.02M-2.47M-1.50M-11.20M-7.16M
Capital expenditure————10,153
Free cash flow————-7.18M
Investing cash flow————-71,550
Financing cash flow1.99M2.50M1.34M11.23M4.09M
Depreciation & amortization0018,43518,436—
Stock-based compensation2.05M500,263951,0651.23M—

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.